

**Supplementary Table S5. Geometric mean (and gCV%) key dose-normalized pharmacokinetic parameters of nintedanib and its metabolites after multiple oral administration of nintedanib in group I and group II, and patients with Child-Pugh category A and B, for phase I and phase II**

	Group I	Group II	gMean ratio	Child-Pugh A	Child-Pugh B <sup>a</sup>	gMean ratio
	gMean (gCV%)	gMean (gCV%)		gMean (gCV%)	Value	
<b>Nintedanib</b>						
AUC <sub>0-12,ss,norm</sub> ([ng·h/mL]/mg)	1.73 (78.8) <i>n</i> = 19	2.64 (73.6) <i>n</i> = 14	1.53	2.10 (80.8) <i>n</i> = 32	1.37	NC
C <sub>max,ss,norm</sub> ([g/mL]/mg)	0.326 (101) <i>n</i> = 19	0.426 (85.3) <i>n</i> = 14	1.31	0.374 (94.1) <i>n</i> = 32	0.163	NC
fe <sub>0-12,ss</sub> (%)	0.154 (73.5) <i>n</i> = 18	0.276 (88.5) <i>n</i> = 13	1.79	0.198 (88.7) <i>n</i> = 30	0.156	NC
<b>BIBF 1202</b>						
AUC <sub>0-12,ss,norm</sub> ([ng·h/mL]/mg)	3.27 (180) <i>n</i> = 19	7.90 (107) <i>n</i> = 14	2.42	4.71 (170) <i>n</i> = 32	6.50	NC
C <sub>max,ss,norm</sub> ([ng/mL]/mg)	0.469 (186) <i>n</i> = 19	0.936 (102) <i>n</i> = 14	2.00	0.626 (162) <i>n</i> = 32	0.733	NC
<b>BIBF 1202 glucuronide</b>						
AUC <sub>0-12,ss,norm</sub> ([ng·h/mL]/mg)	25.2 (135) <i>n</i> = 18	35.6 (163) <i>n</i> = 14	1.41	29.1 (150) <i>n</i> = 31	35.8	NC
C <sub>max,ss,norm</sub> ([ng/mL]/mg)	2.14 (150) <i>n</i> = 19	3.33 (166) <i>n</i> = 14	1.56	2.56 (162) <i>n</i> = 32	3.31	NC
Abbreviations: fe <sub>0-12,ss</sub> , fraction of analyte excreted unchanged in urine at steady state over the time interval 0 to 12 hours; gCV, geometric mean of the coefficient of variation; NC, not calculated <sup>a</sup> There was only one patient with Child-Pugh category B.						